Gafton B, Morarasu S, Dimofte G. Role of immunotherapy in gastric cancer with liver metastasis. World J Clin Oncol 2024; 15(11): 1383-1389 [PMID: 39582613 DOI: 10.5306/wjco.v15.i11.1383]
Corresponding Author of This Article
Stefan Morarasu, PhD, Surgeon, Second Department of Surgical Oncology, Regional Institute of Oncology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Strada Universității 16, Iasi 700115, Romania. morarasu.stefan@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Nov 24, 2024; 15(11): 1383-1389 Published online Nov 24, 2024. doi: 10.5306/wjco.v15.i11.1383
Role of immunotherapy in gastric cancer with liver metastasis
Bogdan Gafton, Stefan Morarasu, Gabriel Dimofte
Bogdan Gafton, Department of Oncology, Regional Institute of Oncology, Iasi 700483, Romania
Bogdan Gafton, Department of Oncology, Grigore T. Popa University of Medicine and Pharmacy, Iasi 700115, Romania
Stefan Morarasu, Second Department of Surgical Oncology, Regional Institute of Oncology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iasi 700115, Romania
Gabriel Dimofte, Department of Surgery, University of Medicine and Pharmacy Grigore T. Popa Iaşi, Regional Institute of Oncology Iasi, Iasi 700483, Romania
Author contributions: Gafton B and Dimofte G designed the editorial; Gafton B and Morarasu S performed the literature review, wrote the manuscript and submitted the study; Dimofte G critically reviewed the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Stefan Morarasu, PhD, Surgeon, Second Department of Surgical Oncology, Regional Institute of Oncology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Strada Universității 16, Iasi 700115, Romania. morarasu.stefan@gmail.com
Received: March 20, 2024 Revised: September 8, 2024 Accepted: September 23, 2024 Published online: November 24, 2024 Processing time: 207 Days and 14.4 Hours
Abstract
Gastric cancer continues to be a significant issue for public health, marked by its widespread occurrence and high mortality rates, even as the incidence of the disease shows a declining trend. The liver is the primary site for metastatic spread, with the peritoneum, lungs, and bones also being common targets. With the advent of biologic treatments and the introduction of immunotherapy for patients with metastatic conditions, the options to treat metastatic gastric cancer have expanded. This diversified therapeutic approach is designed to enhance patient quality of life and prolong survival, showcasing the progress in treatment modalities for individuals with gastric cancer and liver metastases.
Core Tip: Liver metastases are the most common site of metastatic disease in gastric cancer. The benefit of immunotherapy in metastatic gastric cancer varies accordingly. This editorial provides a short overview of the benefit of immunotherapy in metastatic gastric cancer with emphasis on the impact of liver metastasis on treatment outcomes.
